Coherus Biosciences | CHRS - Pre Tax Profit


Coherus Biosciences reported $-46.35M in Pre-Tax Profit for its fiscal quarter ending in December of 2025.





Pre Tax Profit Change Date
AbbVie USD 5.57B 2.9B Mar/2026
Acadia Pharmaceuticals USD 3.98M 22.34M Mar/2026
Akebia Therapeutics USD -11.24M 12.39M Dec/2025
ALKERMES USD -61.93M 122.3M Mar/2026
Alnylam Pharmaceuticals USD 221.65M 60.52M Mar/2026
Amarin USD -852K 7.26M Dec/2025
Amgen USD 1.51B 2.41B Dec/2025
Baxter International USD -756M 877M Dec/2025
Biogen USD 377.7M 433.7M Mar/2026
BioMarin Pharmaceutical USD 141.2M 168.36M Mar/2026
Bristol-Myers Squibb USD 1.47B 1.64B Dec/2025
Coherus Biosciences USD -46.35M 90.86M Dec/2025
Eli Lilly USD 8.27B 1.03B Dec/2025
Fujifilm JPY 104.44B 4.16B Mar/2026
Gilead Sciences USD 2.08B 1.56B Dec/2025
Ironwood Pharmaceuticals USD 68.02M 30.2M Sep/2025
Merck USD 3.42B 3.32B Dec/2025
Myriad Genetics USD 4.6M 3.4M Dec/2025
Pacira USD 571K 8.95M Dec/2025
Perrigo USD -1.33B 1.35B Dec/2025
Pfizer USD 5.18B 6.82B Mar/2026
PTC Therapeutics USD -2.46M 136.62M Mar/2026
Regeneron Pharmaceuticals USD 1.04B 719.6M Dec/2025
Sarepta Therapeutics USD 343.17M 750.85M Mar/2026
Teva Pharmaceutical Industries USD 753M 662M Mar/2026
Vertex Pharmaceuticals USD 1.25B 78.1M Mar/2026
Xencor USD -128.64M 124.37M Mar/2026
Zoetis USD 761M 126M Dec/2025